Novartis Ends Mid-Stage Fabhalta Trial for Kidney Condition
Novartis terminated the study, citing “strategic considerations,” according to a federal clinical trials registry.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Novartis ends mid — stage Fabhalta trial targeting serious kidney condition
Oct 16 (Reuters) — Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a serious kidney condition, citing "strategic considerations", according to a federal clinical trials registry. The trial was evaluating whether the oral medication was safe and effective for treating